COMMUNIQUÉS West-GlobeNewswire

Sundance Biosciences Announces Presentation of Phase 1 Results for SUN-627, a Brain-Penetrant TYK2 Inhibitor for the Treatment of Multiple Sclerosis (MS)
21/10/2026
SUN-627 demonstrated favorable safety, tolerability, and pharmacokinetics for oral, once-daily dosing in healthy volunteers Achieved full central nervous system (CNS) penetration and >90% inhibition of TYK2 pathway [...]
Satellos to Participate in Upcoming Investor Conferences
21/10/2026
TORONTO, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL), a clinical-stage company developing potentially life-improving medicines to treat degenerative muscle diseases, today [...]
Roivant and Priovant Announce Positive Results in CLARITY-1 and CLARITY-2 Phase 3 Trials for Brepocitinib in Non-Infectious Uveitis (NIU)
21/10/2026
Brepocitinib 45 mg once-daily achieved statistically significant benefit compared to placebo on the primary and all key secondary endpoints for each of CLARITY-1 and CLARITY-2, the two identical Phase 3 trials [...]
Immunovant to Report Financial Results for the Second Fiscal Quarter Ended September 30, 2026, and Provide Business Update on Monday, November 9, 2026
21/10/2026
DURHAM, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT ) today announced that it will report its financial results for the second fiscal quarter ended September 30, 2026 on Monday, November 9, [...]
BioCryst Announces U.S. FDA Approval of ORLADEYO® 150 mg Oral Pellets for Adults and Adolescents with HAE
21/10/2026
—Expands BioCryst portfolio of targeted oral prophylactic therapy options to meet patients’ individual needs and preferences— —ORLADEYO is the first and only targeted oral prophylactic therapy with options for HAE [...]
Entrada Therapeutics Appoints Linea Aspesi as Chief People Officer
21/10/2026
A seasoned global people leader and organizational strategist, Ms. Aspesi will help scale Entrada’s people and organization for its next phase of growth BOSTON, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Entrada Therapeutics, [...]
P-Protect Introduces P-Protect Patch - A New Patch-Based Option for Men’s Prostate Wellness
21/10/2026
P-Protect Patch is a men's wellness product that brings prostate health awareness, ingredient transparency, responsible use, and informed healthcare decisions into the conversation. New York, Oct. 21, 2026 (GLOBE [...]
Neuronetics to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call
21/10/2026
MALVERN, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a leader in interventional mental health that combines its NeuroStar® TMS technology with direct patient care through the Greenbrook [...]
TaiMed Biologics Reports IDWeek 2026 Data Highlighting TMB-365 and Its Potential Across Long-Acting HIV Combinations
21/10/2026
Phase 1 results demonstrate TMB-365 antiviral activity and tolerability, supporting continued development as a differentiated antibody for combination HIV treatment Complementary laboratory susceptibility findings [...]
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
21/10/2026
-- Preclinical study demonstrates positive effects of sotagliflozin on cardiac function and structure in hypertrophic cardiomyopathy -- -- Second preclinical study shows inhibitory effects of sotagliflozin on platelet [...]
HeartSciences Files Definitive Proxy Statement for Proposed Business Combination with Fortitude Mining
21/10/2026
Shareholder Special Meeting Scheduled for November 19, 2026 Definitive proxy statement filed with the SEC, marking an important milestone toward completion of the proposed transaction HeartSciences Board of Directors [...]
Achieve Life Sciences Presents 52-Week Cytisinicline Results for Smoking and Vaping Cessation at CHEST 2026
21/10/2026
Nearly one in three adults who were still smoking or vaping after a prior ORCA trial had quit at the end of a year of cytisinicline treatment, with quit rates rising through the year Among the participants new to [...]
10X Health Launches Metabolism Genetic Test
21/10/2026
A saliva-based test provides genetic insights to help inform personalized nutrition and weight-management plans SCOTTSDALE, Ariz., Oct. 21, 2026 (GLOBE NEWSWIRE) -- 10X Health , a leader in personalized health [...]
Pluri Chairman and Active Investor Alejandro Weinstein to Acquire EIB Loan, in Strong Vote of Confidence in the Company
21/10/2026
Chairman-led transaction marks the first step in a broader series of actions to provide a more flexible framework to support the Company's commercial plans HAIFA, Israel, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. ( [...]
IMUNON Announces Strategic Sale of ThermoDox®
21/10/2026
Agreement with VoxelDox Therapeutics, Inc. Creates a Clear Path to Future Value, Subject to Achievement of Development Milestones in the Planned Phase 1 Glioblastoma Trial Sale Reinforces IMUNON's Commitment to Its Core [...]
Onicor Appoints Antifungal Pioneer Piet De Doncker, PhD, as CEO to Advance Personalized Treatment for Fungal Nail Infections
21/10/2026
Developer of itraconazole pulse therapy to lead Onicor's personalized nail orthosis for onychomycosis, a common and hard-to-treat condition, into its next phase TILBURG, the Netherlands, 21 October 2026 – Onicor , a [...]
Santa Ana Bio to Present Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026
21/10/2026
ALAMEDA, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate ( [...]
VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling
21/10/2026
Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials SAN DIEGO, Oct. 21, 2026 (GLOBE [...]
Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
21/10/2026
- Robin Swartz, Voyager’s Chief Business and Operating Officer, appointed President, effective immediately; expected to succeed Alfred W. Sandrock, Jr., M.D., Ph.D., as CEO in Q1 2027 - - Dr. Sandrock expected to remain [...]

Pages